Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals
JAMA Dermatology · 2026
DOI: 10.1001/jamadermatol.2026.1305 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Dermatology, 2026. Verfasst von Alisa M Goldstein und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Genetic Predisposition to Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance The prevalence of germline pathogenic variants in familial melanoma genes has primarily been studied in individuals with a personal or family history of cancer, an approach that may introduce ascertainment bias.
Objective
To estimate the prevalence of pathogenic variants in clinically actionable familial melanoma genes and their associated cancer risks. Design, Settings, and Participants This was a genome-first analysis of 2 population-scale genomically ascertained cohorts of individuals registered in the UK Biobank (UKBB) and the US Geisinger MyCode (GMC) databases, each linked with institutional (GMC) or national (UKBB) cancer registry data from 1970 through 2024. Data analyses were conducted from January 2025 through January 2026. Exposures Germline pathogenic variant status in familial melanoma genes. Main Outcomes and Measures Prevalence of pathogenic variants in 8 major familial melanoma genes: ACD , BAP1 , CDKN2A , CDK4 , MITF E318K, POT1 , TERF2IP , and TERT promoter; and associated cancer risks among individuals in the UK and US who had been genomically ascertained. Cancer odds ratios and time to cancer analyses were adjusted for sex, birth year, body mass index, and smoking status.
Results
The analysis included a total of 696 665 individuals who were genomically ascertained, 227 286 (mean [SD] age, 57.7 [19.6] years) from GMC and 469 379 (mean [SD] age, 70.0 [8.0] years) from UKBB. The cohorts were predominantly female (GMC, 60.6%; UKBB, 54.2%), and of European genetic ancestry (GMC, 93.6%; UKBB, 94.2%). The combined prevalence of the pathogenic variants across all genes evaluated— ACD , BAP1 , CDKN2A , CDK4 , MITF E318K, POT1 , TERF2IP , and TERT promoter—ranged from 0.5% (GMC) to 0.9% (UKBB) in both cohorts. Among individuals with multiple cutaneous melanomas or a first cutaneous melanoma diagnosed before age 40 years, pathogenic variant prevalence exceeded the 2.5% threshold commonly used to recommend germline testing for high- and moderate-penetrance cancer susceptibility genes. Case-control analyses replicated established associations for CDKN2A (brain, cutaneous melanoma, head and neck, pancreas), MITF E318K (cutaneous melanoma, kidney), and POT1 (cutaneous melanoma, hematologic, thyroid). Additional associations, either novel or inconsistently reported, were observed for BAP1 (prostate), CDKN2A (biliary tract, breast, nonmelanoma skin, small intestine), MITF E318K (cervix, nasal cavity and middle ear, nonmelanoma skin), and POT1 (myeloma). In both cohorts, individuals with CDKN2A PVs or MITF E318K developed cutaneous melanoma at younger ages than did noncarriers, although age-of-onset patterns for internal cancers were less consistent. Conclusions and Relevance In this cohort study, the prevalence of pathogenic variants in familial melanoma genes and their associated cancer risks were estimated, findings that may inform and revise germline testing recommendations and cancer risk counseling. These data also suggest that the spectrum of cancer risk for several genes may be broader than previously recognized.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, US National Institutes of Health, Rockville, Maryland.
- Department of Genomic Health, Geisinger Clinic, Geisinger Health System, Danville, Pennsylvania.
- Department of Dermatology, Oregon Health & Science University, Portland.
- Wellcome Sanger Institute, Hinxton, United Kingdom.
- Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, US National Institutes of Health, Bethesda, Maryland.
- University of Pittsburgh Medical Center Hillman Cancer Center Melanoma Program, Pittsburgh, Pennsylvania.
Zitieren
APA
Goldstein, A. M., Kim, J., Haley, J. S., Li, J., Smelser, D. T., Rao, H. S., Hatton, J. N., Yang, X. R., Brown, K., Tucker, M. A., Berry, E. G., Waters, A. J., Adams, D. J., Linehan, W. M., Kirkwood, J. M., Kanetsky, P. A., Carey, D. J., Stewart, D. R., & Sargen, M. R. (2026). Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2026.1305
Vancouver
Goldstein AM, Kim J, Haley JS, Li J, Smelser DT, Rao HS, et al. Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals. JAMA Dermatology. 2026. doi:10.1001/jamadermatol.2026.1305
BibTeX
@article{Goldstein2026,
author = {Goldstein, Alisa M and Kim, Jung and Haley, Jeremy S and Li, Jiang and Smelser, Diane T and Rao, H Shanker and Hatton, Jessica N and Yang, Xiaohong R and Brown, Kevin and Tucker, Margaret A and Berry, Elizabeth G and Waters, Andrew J and Adams, David J and Linehan, W Marston and Kirkwood, John M and Kanetsky, Peter A and Carey, David J and Stewart, Douglas R and Sargen, Michael R},
title = {Prevalence of Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals},
journal = {JAMA Dermatology},
year = {2026},
doi = {10.1001/jamadermatol.2026.1305}
}
EUVIMED